Taxanes in the Treatment of Advanced Gastric Cancer (Q26747708)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

2 April 2020

review article

2 references

18 July 2021

Taxanes in the Treatment of Advanced Gastric Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

cell population proliferation

2 April 2020

main subject

1 reference

18 July 2021

1 reference

18 July 2021

Byung Woog Kang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

2 April 2020

Oh-Kyoung Kwon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

2 April 2020

Wansik Yu

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

2 April 2020

language of work or name

English

0 references

publication date

17 May 2016

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

2 April 2020

18 July 2021

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

2 April 2020

18 July 2021

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

2 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution

2 April 2020

copyright license

1 reference

18 July 2021

0 references

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Docetaxel: its role in current and future treatments for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Paclitaxel chemotherapy for the treatment of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Management of advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

The role of S-1 in the treatment of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Chemotherapy for metastatic gastric cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Preclinical profile of cabazitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Taxol: the chemistry and structure-activity relationships of a novel anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Phase II multi-institutional prospective randomised trial comparing S-1 paclitaxel with S-1 cisplatin in patients with unresectable and/or recurrent advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Is there a role for second-line chemotherapy in advanced gastric cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Paclitaxel and immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Recent developments in taxane drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Paclitaxel formulations: challenges and novel delivery options.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Scheduling of taxanes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES21050651

Managing taxane toxicities

21 January 2018

1 reference

12 December 2020

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group

1 reference

12 December 2020

A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy

1 reference

12 December 2020

Optimal indications for second-line chemotherapy in advanced gastric cancer

1 reference

12 December 2020

Update on taxane development: new analogs and new formulations

1 reference

12 December 2020

Phase II study of Taxol in patients with advanced gastric carcinoma

1 reference

12 December 2020

10.3390/MOLECULES21050651

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27196887 AND SRC:MED&resulttype=core&format=json

2 April 2020

PubMed publication ID

27196887

1 reference